Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sorafenib XS005 vs Nexavar in Healthy Males
NCT05967377Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid carcinoma (TC) (3 arms), sponsored by Xspray Pharma. Primary endpoints: Time of Maximum Observed Plasma Concentration at Day 4, Maximum Observed Plasma Concentration at Day 4 and 4 more. Started Nov 2018; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT05967377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967377.